Literature DB >> 10997414

Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy?

H Zylberberg, B Nalpas, S Pol, C Bréchot, J P Viard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997414     DOI: 10.1097/00002030-200009080-00025

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Association between hepatitis C virus coinfection and regional adipose tissue volume in HIV-infected men and women.

Authors:  Phyllis C Tien; Peter Bacchetti; Barbara Gripshover; E Turner Overton; David Rimland; Don Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

2.  Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients.

Authors:  P F Grima; R Chiavaroli; P Grima
Journal:  Radiol Med       Date:  2008-10-25       Impact factor: 3.469

3.  Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Authors:  Pablo Tebas; Jiameng Zhang; Kevin Yarasheski; Scott Evans; Margaret A Fischl; Abby Shevitz; Judith Feinberg; Ann C Collier; Cecilia Shikuma; Barbara Brizz; Fred Sattler
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

4.  New and emerging agents in the management of lipodystrophy in HIV-infected patients.

Authors:  Eric Bonnet
Journal:  HIV AIDS (Auckl)       Date:  2010-09-17

5.  Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.

Authors:  Edana Cassol; Vikas Misra; Alexander Holman; Anupa Kamat; Susan Morgello; Dana Gabuzda
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.